New Drug Shows Promise in Blocking Diabetes Complications & Boosting Healing

A newly identified experimental compound, RAGE406R, is showing promise in preclinical studies as a potential treatment to address the underlying causes of damage associated with both Type 1 and Type 2 diabetes. Unlike current treatments that primarily focus on managing blood sugar levels, this compound targets a specific protein interaction that drives inflammation and organ injury in diabetes, offering a potentially new avenue for therapy.

Researchers at NYU Langone Health discovered that RAGE406R effectively prevents the interaction between two proteins, RAGE (receptor for advanced glycation end products) and DIAPH1. This interaction is a key contributor to heart and kidney injury, and it likewise slows down wound healing in individuals with diabetes. The findings, published recently in Cell Chemical Biology, suggest a way to ease swelling in affected tissues and accelerate tissue repair.

Understanding the RAGE-DIAPH1 Connection

To understand the significance of this discovery, it’s important to know how RAGE and DIAPH1 contribute to diabetic complications. RAGE is a receptor protein that binds to advanced glycation end products (AGEs). AGEs are formed when sugars attach to proteins or fats – a process that happens more frequently in people with diabetes and obesity, and also increases with age. These AGEs accumulate in the bloodstream and contribute to inflammation and tissue damage. NYU Langone News explains that RAGE essentially acts as a sensor for these damaging molecules.

DIAPH1, plays a role in building the cell’s internal structure, specifically actin filaments. The research team found that DIAPH1 connects to RAGE, and this connection intensifies the complications of diabetes. By blocking this connection, RAGE406R disrupts the process that leads to inflammation and tissue damage.

From RAGE229 to RAGE406R: Improving Safety and Efficacy

This isn’t the first attempt by the NYU Langone Health team to target the RAGE-DIAPH1 pathway. Previously, they identified a compound called RAGE229 that showed promising results in initial studies. However, RAGE229 failed a standard safety test due to structural features that could potentially alter DNA and increase cancer risk. RAGE406R was specifically designed to address this safety concern by removing the problematic structural element. Physician Focus highlights this crucial improvement in the compound’s profile.

Testing of RAGE406R in mice with obesity and Type 2 diabetes demonstrated accelerated wound closure when the compound was applied topically. This suggests a potential for localized treatment of diabetic ulcers, a common and serious complication of the disease.

Calming Inflammation to Promote Healing

A significant part of RAGE406R’s benefit appears to stem from its impact on the immune system. In diabetes, inflammation often occurs in the wrong places or persists for too long, hindering the healing process. The compound works by reducing levels of CCL2, a signaling molecule that promotes inflammation. By lowering CCL2 activity, RAGE406R calms inflammation in macrophages – a type of immune cell – and supports structural remodeling in tissues, which is essential for healing.

What This Means for Diabetes Treatment

Currently, most diabetes treatments focus on managing blood sugar levels. Even as effective in controlling symptoms, these treatments don’t address the underlying causes of diabetic complications. RAGE406R offers a different approach by targeting the inflammatory processes that contribute to organ damage and impaired wound healing. As Dr. Ann Marie Schmidt, co-senior study author and Dr. Iven Young Professor of Endocrinology at NYU Grossman School of Medicine, stated, “Our work shows that RAGE406R can—not by lowering the high blood sugar, but instead by blocking the intracellular action of RAGE.”

This approach could potentially fill gaps in treatment, particularly for individuals with Type 1 diabetes, where current drug options are limited. However, it’s crucial to remember that these findings are from preclinical studies in mice and human cells. Further testing in human clinical trials is necessary to confirm the safety and efficacy of RAGE406R.

Looking Ahead: Clinical Trials and Further Research

The research team is now focused on preparing for human clinical trials to evaluate the potential of RAGE406R as a treatment for diabetic complications. These trials will be essential to determine the appropriate dosage, assess potential side effects, and confirm the compound’s effectiveness in humans. NYU Langone’s Technology Opportunities & Ventures notes that the study results also provide a foundation for developing biomarkers to measure the treatment’s effectiveness in live animals and, eventually, in human patients.

The development of RAGE406R represents a significant step forward in understanding and potentially treating the root causes of diabetic complications. While more research is needed, this discovery offers hope for a future where diabetes-related damage can be prevented or reversed, improving the lives of millions affected by this chronic disease. Individuals with diabetes should continue to follow the guidance of their healthcare providers and adhere to established treatment plans while awaiting the results of future clinical trials.